No Data
PKU HealthCare's Drug for Schizophrenia, Bipolar Gets Nod for Registration
pku healthcare corp., (000788.SZ) has been approved as the holder of the marketing authorization for "oseltamivir phosphate granules for oral suspension"
pku healthcare corp. (000788.SZ) announced that recently, the company has received the approval and issuance from the National Medical Products Administration...
pku healthcare corp. (000788.SZ): Received the pharmaceutical registration certificate for hydrobromide vortioxetine tablets.
On November 29, pku healthcare corp. (000788.SZ) announced that it has recently received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration. The generic name of the pharmaceutical is Hydrobromide Venlafaxine Tablets, with specifications including 5mg, 10mg, 20mg, and registered under the classification of chemical drug category 4. Venlafaxine is a new antidepressant drug launched in 2013, which has good clinical effectiveness, prominent clinical characteristics, and good safety. It can inhibit the reuptake of serotonin (5-HT) leading to enhanced serotonin activity, and also has antagonistic action on 5-HT3 receptors and stimulating action on 5-HT1A receptors.
pku healthcare corp. (000788.SZ) plans to distribute a cash dividend of 0.5 yuan per 10 shares, with ex-rights and ex-dividends on November 27.
pku healthcare corp. (000788.SZ) announced that the proposed interim equity distribution for the first half of 2024 is: to all shareholders of the company...
pku healthcare corp. (000788.SZ): Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets Approved.
格隆汇 October 29th | pku healthcare corp. (000788.SZ) announced that recently, pku healthcare corp. limited received the "Drug Registration Certificate" of Paroxetine Hydrochloride Enteric-coated Sustained-release Tablets issued by the National Medical Products Administration. Paroxetine Hydrochloride Enteric-coated Sustained-release Tablets (hereinafter referred to as "Paroxetine Enteric-coated Sustained-release Tablets") is a potent, highly selective selective serotonin reuptake inhibitor (SSRI) that enhances central serotonin nerve function by increasing serotonin concentrations in the synaptic cleft, improving depressive symptoms. Currently, Paroxetine has been recommended by multiple domestic and foreign treatment guidelines for the treatment of depression.
Peking University Pharmaceuticals: Report for the third quarter of 2024
PKU HealthCare Corp.,Ltd.'s (SZSE:000788) 28% Share Price Plunge Could Signal Some Risk
No Data
